JPWO2020214867A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020214867A5 JPWO2020214867A5 JP2021561905A JP2021561905A JPWO2020214867A5 JP WO2020214867 A5 JPWO2020214867 A5 JP WO2020214867A5 JP 2021561905 A JP2021561905 A JP 2021561905A JP 2021561905 A JP2021561905 A JP 2021561905A JP WO2020214867 A5 JPWO2020214867 A5 JP WO2020214867A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- fusion protein
- variant icosl
- icosl
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (37)
前記aGVHDが、免疫抑制剤による処置に対して抵抗性もしくは難治性であり、任意で、免疫抑制剤がコルチコステロイドもしくはシクロスポリンを含む、
請求項5もしくは請求項7記載の医薬または請求項6もしくは請求項7記載の使用。 said aGvHD is Grade II-IV aGVHD, and/or
said aGVHD is resistant or refractory to treatment with an immunosuppressive agent, optionally wherein the immunosuppressive agent comprises a corticosteroid or cyclosporine;
A medicament according to claim 5 or claim 7 or a use according to claim 6 or claim 7 .
任意で、コロナウイルスがSARS-CoV-2であり、前記感染症がCOVID-19である、
請求項9もしくは請求項11記載の医薬または請求項10もしくは請求項11記載の使用。 the virus is a coronavirus,
optionally, the coronavirus is SARS-CoV-2 and said infectious disease is COVID-19;
A medicament according to claim 9 or claim 11 or a use according to claim 10 or claim 11 .
(a)該Fc領域が、野生型ヒト免疫グロブリンのFcと比較して低下したエフェクター機能を示すバリアントFc領域である、および/または
(b)該Fc領域が、野生型ヒトIgG1と比較して1つもしくは複数のアミノ酸置換を含むバリアントIgG1 Fc領域である、
請求項1、3、5、7~9、11~25、および27~34のいずれか一項記載の医薬または請求項2、3、6、7、8、10~24、および26~34のいずれか一項記載の使用。 said multimerization domain is or comprises the Fc region of an immunoglobulin, optionally
(a) said Fc region is a variant Fc region that exhibits reduced effector function compared to the Fc of a wild-type human immunoglobulin, and/or
(b) the Fc region is a variant IgG1 Fc region comprising one or more amino acid substitutions compared to wild-type human IgG1;
The medicament of any one of claims 1, 3, 5, 7-9, 11-25, and 27-34 or the medicament of claims 2, 3, 6, 7, 8, 10-24, and 26-34 Use according to any one.
(b)前記バリアントFc領域がK447delをさらに含み、該残基がKabatのEUインデックスに従って番号が付けられている、
請求項35もしくは36記載の医薬または請求項35もしくは36記載の使用。 (a) said variant Fc region further comprises the amino acid substitution C220S, wherein said residues are numbered according to the EU index of Kabat, or
(b) said variant Fc region further comprises K447del, wherein said residues are numbered according to the EU index of Kabat;
37. A medicament according to claim 35 or 36 or a use according to claim 35 or 36 .
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962835488P | 2019-04-17 | 2019-04-17 | |
US62/835,488 | 2019-04-17 | ||
US201962855830P | 2019-05-31 | 2019-05-31 | |
US62/855,830 | 2019-05-31 | ||
US201962931212P | 2019-11-05 | 2019-11-05 | |
US62/931,212 | 2019-11-05 | ||
US201962945071P | 2019-12-06 | 2019-12-06 | |
US62/945,071 | 2019-12-06 | ||
US202062962832P | 2020-01-17 | 2020-01-17 | |
US62/962,832 | 2020-01-17 | ||
US202062987854P | 2020-03-10 | 2020-03-10 | |
US62/987,854 | 2020-03-10 | ||
PCT/US2020/028601 WO2020214867A1 (en) | 2019-04-17 | 2020-04-16 | Methods and uses of variant icos ligand (icosl) fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022529059A JP2022529059A (en) | 2022-06-16 |
JPWO2020214867A5 true JPWO2020214867A5 (en) | 2023-04-24 |
Family
ID=70554252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021561905A Pending JP2022529059A (en) | 2019-04-17 | 2020-04-16 | Methods and Uses of Variant ICOS Ligand (ICOSL) Fusion Proteins |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220218785A1 (en) |
EP (1) | EP3955953A1 (en) |
JP (1) | JP2022529059A (en) |
KR (1) | KR20220035032A (en) |
CN (1) | CN114302736A (en) |
AU (1) | AU2020257238A1 (en) |
BR (1) | BR112021020447A2 (en) |
CA (1) | CA3136816A1 (en) |
IL (1) | IL287290A (en) |
MX (1) | MX2021012607A (en) |
SG (1) | SG11202111033VA (en) |
WO (1) | WO2020214867A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200085777A (en) | 2017-10-18 | 2020-07-15 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Variant ICOS ligand immunomodulatory protein and related compositions and methods |
CN116903727A (en) | 2020-05-08 | 2023-10-20 | 高山免疫科学股份有限公司 | APRIL and BAFF inhibitory immunomodulatory proteins with and without T cell inhibitory proteins and methods of use thereof |
US20230408515A1 (en) * | 2020-11-10 | 2023-12-21 | Massachusetts Institute Of Technology | Engineered protein for rapid, efficient capture of pathogen-specific antibodies |
KR20230155960A (en) * | 2022-05-03 | 2023-11-13 | 고려대학교 산학협력단 | ICOS-L variants with enhanced binding to ICOS |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
WO1992019266A1 (en) | 1991-05-06 | 1992-11-12 | The United States Of America, As Represented By The Department Of Health And Human Services | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
EP0783573B1 (en) | 1994-09-23 | 2005-12-21 | The University of British Columbia | Method of enhancing expression of mhc class i molecules bearing endogenous peptides |
ES2154738T3 (en) | 1994-10-03 | 2001-04-16 | Us Gov Health & Human Serv | COMPOSITION THAT INCLUDES A RECOMBINANT VIRUS EXPRESSING AN ANTIGEN AND A RECOMBINATING VIRUS EXPRESSING AN IMMUNO STIMULATORY MOLECULA. |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
SE506700C2 (en) | 1996-05-31 | 1998-02-02 | Mikael Kubista | Probe and Methods for Analysis of Nucleic Acid |
PT912766E (en) | 1996-06-04 | 2009-07-16 | Univ Utah Res Found | Monitoring hybridization during pcr |
AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK1068241T3 (en) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antibody variants and fragments thereof |
GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
GB9812768D0 (en) | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
NZ509974A (en) | 1998-08-07 | 2003-10-31 | Univ Washington | Immunological herpes simplex virus antigens and methods for use thereof |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (en) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polypeptide comprising an Fc region of variant human IgG1 |
AU781958C (en) | 1999-08-09 | 2006-03-30 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
ES2267803T3 (en) | 2000-08-11 | 2007-03-16 | University Of Utah Research Foundation | PROBLEMS OF INDIVIDUAL MARKING OLIGONUCLEOTIDES. |
DE60235041D1 (en) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | AND YOUR USE |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
ITCZ20020002A1 (en) | 2002-04-11 | 2003-10-13 | Parco Scient E Tecnologico Del | DEVICE AND METHOD FOR SIMULTANEOUS DETECTION OF DIFFERENT ANTIBODIES AND ANTIGENS IN CLINICAL, FOOD AND ENVIRONMENTAL SAMPLES |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2005063816A2 (en) | 2003-12-19 | 2005-07-14 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
WO2006060314A2 (en) | 2004-12-01 | 2006-06-08 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
TR201802323T4 (en) | 2007-12-11 | 2018-03-21 | Univ North Carolina Chapel Hill | Polypurine pathway modified retroviral vectors. |
ES2668895T3 (en) | 2011-03-16 | 2018-05-23 | Amgen Inc. | Fc variants |
EP2694099B1 (en) | 2011-04-08 | 2019-10-16 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
CN117462693A (en) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | XTEN conjugate compositions and methods of making the same |
MX2015011670A (en) | 2013-03-15 | 2016-03-31 | Biogen Ma Inc | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies. |
WO2014207748A1 (en) | 2013-06-27 | 2014-12-31 | Alexander Biro | Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease |
WO2015107026A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
KR20240046641A (en) * | 2015-04-17 | 2024-04-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Immunomodulatory proteins with tunable affinities |
MX2018012472A (en) * | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof. |
KR20200085777A (en) * | 2017-10-18 | 2020-07-15 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Variant ICOS ligand immunomodulatory protein and related compositions and methods |
-
2020
- 2020-04-16 JP JP2021561905A patent/JP2022529059A/en active Pending
- 2020-04-16 AU AU2020257238A patent/AU2020257238A1/en active Pending
- 2020-04-16 EP EP20724339.5A patent/EP3955953A1/en active Pending
- 2020-04-16 SG SG11202111033VA patent/SG11202111033VA/en unknown
- 2020-04-16 WO PCT/US2020/028601 patent/WO2020214867A1/en unknown
- 2020-04-16 CA CA3136816A patent/CA3136816A1/en active Pending
- 2020-04-16 CN CN202080043309.2A patent/CN114302736A/en active Pending
- 2020-04-16 KR KR1020217037579A patent/KR20220035032A/en unknown
- 2020-04-16 BR BR112021020447A patent/BR112021020447A2/en unknown
- 2020-04-16 US US17/603,827 patent/US20220218785A1/en active Pending
- 2020-04-16 MX MX2021012607A patent/MX2021012607A/en unknown
-
2021
- 2021-10-14 IL IL287290A patent/IL287290A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9988459B2 (en) | Anti-IFNAR1 antibodies with reduced Fc ligand affinity | |
JP2020120689A5 (en) | ||
Saadoun et al. | Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies | |
AU2002306651B2 (en) | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists | |
JP2020002172A5 (en) | ||
CN106102837B (en) | Bispecific HIV-1-neutralizing antibodies | |
JP2010527621A5 (en) | ||
TW201526923A (en) | Stable high protein concentration formulations of human anti-TNF-alpha antibodies | |
JP2012510282A5 (en) | ||
JP2019503706A5 (en) | ||
EP3201231A1 (en) | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 | |
JPWO2020214867A5 (en) | ||
Reiff | A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation | |
JP2019527676A5 (en) | ||
JP2022539785A (en) | TACI-Fc fusion protein and use thereof | |
Lin et al. | Intramuscular Ibalizumab: pharmacokinetics, safety and efficacy vs IV Administration | |
Alba et al. | Seven clinical conundrums in the treatment of ANCA-associated vasculitis | |
Michalova et al. | Biologic agents in the management of inflammatory eye diseases | |
Dietrich | HIV-1 entry inhibitors | |
AU2021413653A1 (en) | Formulation containing soluble gp130 dimer and method for using same | |
EP4095156A1 (en) | Neutralizing antibodies against hepatitis c virus | |
CA3176673A1 (en) | Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease | |
CN112007034B (en) | Application of combination of TLR agonist, immune checkpoint inhibitor and VEGFR inhibitor in preparation of drugs for treating tumors | |
Majumder et al. | Biologicals in the Treatment of Non-Infectious Uveitis | |
Guillevin | Synchronization of plasma exchange and adjuvant treatments |